Conference Day - 8th October


The conference day includes executive panels outlining capital market dynamics, big pharma market appetite, clinical, regulatory and commercialisation drivers, finance raising & partnerships and emerging healthcare models.

There are also 4x intimate and practical workshops on clinical development, regulatory approval, licensing strategies and market access and reimbursement.

08:00


Registration and Breakfast

09:00


Keynote Presentation: Capital Markets Outlook
Marshall Smith, Head of Global Healthcare, Goldman Sachs

09:20


 
Investor Panel: Macro Trends, Market Corrections and Unmet Medical Need

What are the factors currently fuelling VC and public markets, how are these affecting the entrepreneurial scene and more well established firms and how do executives see these impacting appetite and strategies for investing and company building? Plus, with prominent reloads, what areas are grabbing investor’s attention?

Todd Foley, Managing Partner, MPM Capital
Ricky Sun, Partner, Life Sciences, Bain Capital
Meredith Fisher, Partner, Partners Healthcare
Alan Crane, Entrepreneur Partner, Polaris Partners
Joshua Resnick,
Managing Partner, RA Capital Management
 

10:00


Pharma Panel: Strategic Shifts in Addressing Pipeline Drift; Pharma M&A and Partnering in 2020

Not withstanding the legacy factors continuing to influence strong deal flow, how is Pharma responding to the emerging encroachment of tech giants into their territories? Does this present co-operation opportunities or unwelcome competition and how will this impact external M&A, partnering and consolidation strategies?

Moderator: Senior Executive, Goldman Sachs TBC
Jay Stamatis, Vice President, Head of Business Development and Acquisitions, Abbvie
Veronique Riethuisen, SVP, Global Head of Business Development & Alliance Management, Ipsen
Philippe Lopes-Fernandes, SVP, Global Head of BD & Alliance Management, Merck Serono
Beyhan Zaim, SVP, Commercial Business Development, Novo Nordisk
Nigel Sheail, Global Head of Mergers & Acquisitions and Business Development & Licensing, Novartis

10:40


Networking Break

11:10


Corporate Investor Panel: Nothing Ventured, Nothing Gained; Backing Bigger Rounds and Making Bigger Bets

With the size of the average investment rounds getting bigger across the entire venture industry how are CVCs aligning with this trend? What can we expect to see from CVCs in terms of leading investment rounds and how is the macro environment affecting the approaches CVCs are taking. Plus, executives share some insights into their current investment preferences.

Peter Dudek, Partner, MRL Ventures Fund
Priyanka Rohatgi, Managing Director, Head, Ipsen Ventures
Michal Silverberg, Managing Director, Novartis Venture Fund
Adam Houghton, Vice President and Head, AbbVie Ventures

11:50


Executive Panel: Raising the Bar; Making the ‘Series’ A Grade

In an industry becoming increasingly defined by weighty Series A’s, executives who have been instrumental in achieving strategically significant early-stage venture raises share their success stories and war stories in equal measure. Plus, share what we can expect to see from their companies as they continue to deploy their capital.

David De Graaf, CEO, Comet Therapeutics
Alexandra Gluckmann, CEO, Cedilla Therapeutics
Michael Pavia
, CEO, Tuned Therapeutics                                                             

Andrew ElBardissi, Principal, Deerfield Management

12:20


Executive Panel: Leveraging Strategic Partnerships to Accelerate the progress of your molecule(s)

Executives who have taken their company through key clinical milestones debate the key challenge and success factors in finding the right partners, patient recruitment and risk management approaches to take their assets cost-effectively and punctually through clinical trials.

Moderator: Kenneth Barr, SVP, Head of Discovery Services, Syngene
Additional panelists details to follow shortly


LSX Pharma BD Forum 200x    Licensing and collaboration workshop-1LSX Clinical Workshop 200x LSX 1-2-1 Partnering 200x

See a full description here

13:00


Networking Lunch

13:50


Executive Panel: De-Risking the Regulatory Approval Path - How to Optimize Your Investment Dollars

The path to global product approval is notorious for hurdles from every angle; from technical/scientific risk to regulatory and market access risk. The hurdles are even more evident when there is limited or no precedent for the indication being sought that could impact time, cost and approvability. Executives explore the best ways to minimize these risks and probe cases that address these issues during development, sharing de-risking strategies for keep innovative programs on track.

Moderator: Laurie Smaldone Alsup, MD, CSO, NDA Group
Ed Kaye, CEO, Stoke Therapeutics
Ailis Tweed-Kent, CEO, Cocoon Biotech

John Glasspool, CEO, Anthos Therapeutics
Christine Swenson
, Head, Regulatory Affairs, Moderna Therapeutics

14:30


Keynote Chat: The Rationale of AI in Healthcare? It’s Human Nature
Ted Tanner Jr., CTO and Chief Architect, Watson Health, IBM
Jay Sales, 
Director, Advanced Technology, VSP Global

14:50


Executive Panel: Commercialization; the Alternative to the Traditional Exit Strategy

The importance of a robust development and commercialization strategy has never been more evident. With decades of experience between them, executives discuss the considerations needed as your drug progresses through the developmental phases towards the market and share their advice on how to minimize the risk that your company’s therapy will end up a commercial failure.

Moderator: Senior executive from IQVIA
Additional panelists details to follow shortly


LSX Pharma BD Forum 200x      Value Pricing-1LSX 1-2-1 Partnering 200x

See a full description here

15:30


Networking Break

16:00


Executive Panel: Movers, Shakers and Therapeutic Deal Makers

With lofty biotech valuations and rising competition in key therapeutic fields, executives who have positioned their companies as attractive for deal making opportunities share their experiences, KSFs and fundamentals when engaging big pharm. Plus executives share what we can expect to see from their respective companies in the year ahead.

Rogerio Vivaldi, CEO, Sigilon Therapeutics
Deanna Petersen,
CBO, AvroBio

Kelly Gold, Vice President, Corporate Development, CAMP4 Therapeutics
Nouhad Husseini, Vice President, Head of Business Development, Regeneron Pharmaceuticals
Constantine
Chinoporos, CBO, Boston Pharmaceuticals

16:40


Closing Panel: Knocking on the Door; the Booming Direct-to-Consumer (D2C) Healthcare Model

With tech players increasingly encroaching in healthcare, forcing companies — as well as startups — to think of different ways to reach patients, and investors wagering that consumers will be increasingly willing to shop for healthcare the same way they buy more traditional products online, what can we expect from the D2C model?

Joel Wishkovsky, CEO, Simple Health
Melissa Fensterstock, Co-Founder and CEO, Lansdowne Labs
Carolyn Witte, Co-Founder and CEO, Tia
Nicole Kholodnov, VP of Clinical Operations, Parsley Health

17:20


Networking Drinks & Close of Conference

DOWNLOAD THE BROCHURE